...
search icon
anl-img

Adlai Nortye Ltd. American Depositary Shares, Common Stock

ANL

NMQ

$2.04

+$0.06

(3.03%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$73.06M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.34K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.85 L
$17.48 H
$2.04

About Adlai Nortye Ltd. American Depositary Shares, Common Stock

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameANLSectorS&P500
1-Week Return1.54%1.76%-2.37%
1-Month Return-13.54%0.33%-3.79%
3-Month Return1.02%-8.58%-0.46%
6-Month Return-43.29%-4.26%3.58%
1-Year Return-78.12%1.27%22.47%
3-Year Return-86.8%5.33%25.17%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue--45.73M-5.00M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":10.93,"profit":true}]
Cost of Revenue1.48M1.51M-2.04M2.22M[{"date":"2019-12-31","value":66.65,"profit":true},{"date":"2020-12-31","value":67.95,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":91.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(1.48M)(1.51M)45.73M(2.04M)2.78M[{"date":"2019-12-31","value":-3.24,"profit":false},{"date":"2020-12-31","value":-3.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4.46,"profit":false},{"date":"2023-12-31","value":6.07,"profit":true}]
Gross Margin--100.00%(Infinity%)55.56%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":55.56,"profit":true}]
Operating Expenses17.64M24.59M54.37M67.27M72.55M[{"date":"2019-12-31","value":24.31,"profit":true},{"date":"2020-12-31","value":33.9,"profit":true},{"date":"2021-12-31","value":74.94,"profit":true},{"date":"2022-12-31","value":92.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(19.12M)(26.10M)(8.65M)(67.27M)(67.55M)[{"date":"2019-12-31","value":-1911704000,"profit":false},{"date":"2020-12-31","value":-2610039000,"profit":false},{"date":"2021-12-31","value":-864600000,"profit":false},{"date":"2022-12-31","value":-6727000000,"profit":false},{"date":"2023-12-31","value":-6755100000,"profit":false}]
Total Non-Operating Income/Expense--(49.37M)8.05M(37.41M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-613.51,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-464.84,"profit":false}]
Pre-Tax Income(17.83M)(63.38M)(56.68M)(58.79M)(104.23M)[{"date":"2019-12-31","value":-1783004200,"profit":false},{"date":"2020-12-31","value":-6337831700,"profit":false},{"date":"2021-12-31","value":-5667800000,"profit":false},{"date":"2022-12-31","value":-5879000000,"profit":false},{"date":"2023-12-31","value":-10422800000,"profit":false}]
Income Taxes(1.00)3.00(46.19M)8.31M643.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-555.68,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.74,"profit":true}]
Income After Taxes--(10.49M)(67.10M)(104.87M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1049000000,"profit":false},{"date":"2022-12-31","value":-6710200000,"profit":false},{"date":"2023-12-31","value":-10487100000,"profit":false}]
Income From Continuous Operations--(56.68M)(58.79M)(104.87M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-5667800000,"profit":false},{"date":"2022-12-31","value":-5879000000,"profit":false},{"date":"2023-12-31","value":-10487100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(17.83M)(63.38M)(56.68M)(58.79M)(104.87M)[{"date":"2019-12-31","value":-1783004200,"profit":false},{"date":"2020-12-31","value":-6337831700,"profit":false},{"date":"2021-12-31","value":-5667800000,"profit":false},{"date":"2022-12-31","value":-5879000000,"profit":false},{"date":"2023-12-31","value":-10487100000,"profit":false}]
EPS (Diluted)----(2.18)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-218,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ANL
Cash Ratio 1.80
Current Ratio 1.85

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANL
ROA (LTM) -46.41%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANL
Debt Ratio Lower is generally better. Negative is bad. 0.50
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.50

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANL
Trailing PE NM
Forward PE NM
P/S (TTM) 14.61
P/B 1.37
Price/FCF NM
EV/R 2.92
EV/Ebitda NM

FAQs

What is Adlai Nortye Ltd. American Depositary Shares share price today?

Adlai Nortye Ltd. American Depositary Shares (ANL) share price today is $2.04

Can Indians buy Adlai Nortye Ltd. American Depositary Shares shares?

Yes, Indians can buy shares of Adlai Nortye Ltd. American Depositary Shares (ANL) on Vested. To buy Adlai Nortye Ltd. American Depositary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Adlai Nortye Ltd. American Depositary Shares be purchased?

Yes, you can purchase fractional shares of Adlai Nortye Ltd. American Depositary Shares (ANL) via the Vested app. You can start investing in Adlai Nortye Ltd. American Depositary Shares (ANL) with a minimum investment of $1.

How to invest in Adlai Nortye Ltd. American Depositary Shares shares from India?

You can invest in shares of Adlai Nortye Ltd. American Depositary Shares (ANL) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Adlai Nortye Ltd. American Depositary Shares shares
What is Adlai Nortye Ltd. American Depositary Shares 52-week high and low stock price?

The 52-week high price of Adlai Nortye Ltd. American Depositary Shares (ANL) is $17.48. The 52-week low price of Adlai Nortye Ltd. American Depositary Shares (ANL) is $1.85.

What is Adlai Nortye Ltd. American Depositary Shares price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Adlai Nortye Ltd. American Depositary Shares (ANL) is

What is Adlai Nortye Ltd. American Depositary Shares price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Adlai Nortye Ltd. American Depositary Shares (ANL) is 1.37

What is Adlai Nortye Ltd. American Depositary Shares dividend yield?

The dividend yield of Adlai Nortye Ltd. American Depositary Shares (ANL) is 0.00%

What is the Market Cap of Adlai Nortye Ltd. American Depositary Shares?

The market capitalization of Adlai Nortye Ltd. American Depositary Shares (ANL) is $73.06M

What is Adlai Nortye Ltd. American Depositary Shares’s stock symbol?

The stock symbol (or ticker) of Adlai Nortye Ltd. American Depositary Shares is ANL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top